Overview

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Radius Pharmaceuticals, Inc.
Treatments:
Hormones